ImmunoGen, Inc. (NASDAQ:IMGN)
| CAPS Rating |
|
|---|
IMGN
VS S&P 500 (SPY)
IMGN News and Commentary
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2 – SeekingAlpha
- An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABP – 247wallst
- Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CY – 247wallst
- This Cancer Drug Works, but Indication Drama Remains – The Motley Fool
- 3rd UPDATE: Roche Breast Cancer Drug Shows Late-Stage Success – SmartMoney
- Roche's Cancer Drug Moves Forward - Analyst Blog – NASDAQ
- UPDATE: New Roche Breast Cancer Drug Shows Late Stage Trial Success – SmartMoney
- Early Submission = 60% Pop – The Motley Fool
- ImmunoGen Beats Up on Analysts Yet Again – The Motley Fool
How do you think IMGN will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
272
Outperform
19
Underperform
All-Star Players
74
Outperform
3
Underperform
Wall Street
9
Outperform
1
Underperform
RSS Headlines
Fool UK
